Treating HCC: Safety Profile Considerations

Opinion
Video

Tanios S. Bekaii-Saab, MD, discusses safety profile considerations for patients undergoing treatment for hepatocellular carcinoma, and the Oncology Brothers recap the entire discussion.

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Related Content
Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC

Russ Conroy
January 10th 2025
Article

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Data from a phase 1b/2 trial show improvements in overall survival with amezalpat plus atezolizumab/bevacizumab among patients with metastatic HCC.

FDA Grants Orphan Drug Designation to Amezalpat in Hepatocellular Carcinoma

Russ Conroy
January 7th 2025
Article

Data from a phase 1b/2 trial show improvements in overall survival with amezalpat plus atezolizumab/bevacizumab among patients with metastatic HCC.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

Adrienne Bruce Shannon, MD;Sean Dineen, MD;Muhammad Talha Waheed, MD
April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

FDA Approves Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma

Roman Fabbricatore;Ariana Pelosci
December 27th 2024
Article

Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

X-ray Brachytherapy Sustains Organ Preservation in Early Rectal Cancer

X-ray Brachytherapy Sustains Organ Preservation in Early Rectal Cancer

Russ Conroy
December 22nd 2024
Article

Data from the phase 3 OPERA trial support contact X-ray brachytherapy boost as a treatment option for preserving organs in smaller rectal adenocarcinoma tumors.